Principal Scientist, Auto-Immunity

San Diego, California, United States
Jun 06, 2021
Biotech Beach
Required Education
Bachelors Degree
Position Type
Full time

  • IPO, clinical stage biotech with lead asset in Ph 1 and potential for first-in-class mechanism
  • First precision medicine approach to GI therapeutics, with platform attracting strong partners
  • Global exclusive license to Cedars-Sinai's GI biobank and bioinformatics platform
  • Fully capitalized with top-tier investor syndicate

Prometheus is a IPO biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD). The company's precision medicine platform, Prometheus 360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is a spin out of Cedars-Sinai Medical Center and partners with the hospital system for its biospecimens, clinical data, and bioinformatics.

The company is led by an exceptional management team bringing deep experience in GI and autoimmune therapies. CEO Mark McKenna joined in 2019 to refocus the organization around a precision therapeutics strategy after orchestrating a successful turnaround effort at Salix Pharmaceuticals. Mark and the executive team are guided by Prometheus' board of directors, led by Chairman Tachi Yamada, M.D., and a scientific advisory board composed of key opinion leaders in IBD, including Stephan Targan, M.D., William Sandborn, M.D. and Dermot P. McGovern, M.D., Ph.D.

The company recently secured a $130 million Series D financing with a top-tier syndicate and is attracting best-in-class collaboration partners such as Takeda and Dr. Falk. With a lead therapeutic program in Phase 1 studies and a robust emerging pipeline, the company is seeking a best-in-class immunologist to lead all of Prometheus' preclinical development efforts and be accountable for delivering a sustainable pipeline of drug candidates, from target validation through IND submission.


  • D., MD or equivalent post-graduate degree in Immunology or related field with at least 10 years of experience in academia and then industry, preferably in the field of auto-immune diseases.
  • Current with emerging new science and technologies relevant to the evaluation of inflammation and fibrosis, including organoids, explants and both transgenic and humanize in vivo Familiar with the integration of bioinformatics and high throughput approaches into target discovery and validation workflows.
  • Experienced with cell-based assays, including primary cells assays, multiplex-cytokine analysis and mechanism of action studies. Solid understanding of immune-phenotyping, including single cell analysis and multi-omics analysis.
  • Familiar with the pharmacology requirements of regulatory submissions and of the drug development process from discovery stage to IND-enabling studies, including therapeutic biologics.
  • Prior experience with biomarkers and precision drug development a plus.
  • Self-motivated with excellent planning, problem-solving, organizational and communication skills. Enjoys training other with an excellent track record of supervising more junior team members.
  • Can independently designs and executes scientific projects and present them to a broad internal audience.

All qualified applicants are considered for employment without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability, veteran status or other protected class.